Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.